Search

Your search keyword '"Eron, J."' showing total 361 results
Start Over Author "Eron, J."
361 results on '"Eron, J."'

2. Changes in the Skin Microbiome Following Dermatological Procedures: A Scoping Review

Author

Jeremy R. Ellis, Eron J. Powell, Luke M. Tomasovic, Rachel L. Marcheskie, Vishruth Girish, Anmol Warman, and Darshan Sivaloganathan

Subjects
skin microbiome, dysbiosis, cutaneous microbiome, dermatological intervention, Microbiology, QR1-502
Abstract

The skin microbiome consists of bacteria, fungi, viruses, and mites, which play a crucial role in maintaining skin health and immune function. Imbalances in this microbial community, known as dysbiosis, are implicated in various dermatological conditions. While skincare products are known to influence the skin microbiome, the effects of dermatological procedures have not been extensively studied. Here, we perform a scoping review to outline the studies investigating the impacts of dermatological interventions on the skin microbiome. Phototherapy emerged as the most studied intervention, encompassing UV phototherapy, light therapy, laser therapy, and photodynamic therapy. Chemical interventions, such as chemical peels, micropigmentation, and debridement, have comparatively limited studies describing their impacts on the skin microbiome. To date, no studies have been done on a wide variety of common dermatological procedures such as cryotherapy, skin grafts, and dermabrasion, which may have stronger likelihoods of affecting the skin microbiome. This underscores the need for further research on the influences of dermatological procedures, especially chemical and physical interventions, on the skin microbiome. More comprehensive pre-clinical and clinical studies are essential not only for understanding the long-term consequences of these procedures, but also for optimizing patient outcomes in dermatological care.

Published
2024
Full Text
View/download PDF

3. Correlates of psychological intimate partner violence with HIV care outcomes on patients in HIV care

Author

Fredericksen, RJ, Nance, RM, Whitney, BM, Harding, BN, Fitzsimmons, E, Del Rio, C, Eron, J, Feaster, DJ, Kalokhe, AS, Mathews, WC, Mayer, KH, Metsch, LR, Mugavero, MJ, Potter, J, O’Cleirigh, C, Napravnik, S, Rodriguez, B, Ruderman, S, JAC, Delaney, and Crane, HM

Subjects
Epidemiology, Health Services and Systems, Public Health, Health Sciences, HIV/AIDS, Drug Abuse (NIDA only), Violence Against Women, Mental Health, Substance Misuse, Behavioral and Social Science, Clinical Research, Violence Research, Mental health, Peace, Justice and Strong Institutions, Anti-Retroviral Agents, Cross-Sectional Studies, HIV Infections, Humans, Intimate Partner Violence, Prevalence, Sexual Partners, Viral Load, Psychological violence, HIV care, Patient reported outcomes, Public Health and Health Services, Health services and systems, Public health
Abstract

BackgroundAmong people living with HIV (PLWH), physical intimate partner violence (IPV) is associated with poor virologic, psychiatric, and behavioral outcomes. We examined non-physical, psychological intimate partner violence (psy-IPV) and HIV care outcomes using data from two U.S. consortia.MethodsWe conducted multivariable analyses with robust standard errors to compare patients indicating/not indicating psy-IPV.ResultsAmong PLWH (n = 5950), 9.5% indicated psy-IPV; these individuals were younger (- 3; 95% CI [- 2,-4], p-value

Published
2021

4. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Author

De Wit, S., Florence, E., Moutschen, M., Van Wijngaerden, E., Vandekerckhove, L., Vandercam, B., Brunetta, J., Conway, B., Klein, M., Murphy, D., Rachlis, A., Shafran, S., Walmsley, S., Ajana, F., Cotte, L., Girardy, P.-M., Katlama, C., Molina, J.-M., Poizot-Martin, I., Raffi, F., Rey, D., Reynes, J., Teicher, E., Yazdanpanah, Y., Gasiorowski, J., Halota, W., Horban, A., Piekarska, A., Witor, A., Arribas, J.R., Perez-Valero, I., Berenguer, J., Casado, J., Gatell, J.M., Gutierrez, F., Galindo, M.J., Gutierrez, M.D.M., Iribarren, J.A., Knobel, H., Negredo, E., Pineda, J.A., Podzamczer, D., Sogorb, J.Portilla, Pulido, F., Ricart, C., Rivero, A., Santos Gil, I., Blaxhult, A., Flamholc, L., Gisslèn, M., Thalme, A., Fehr, J., Rauch, A., Stoeckle, M., Clarke, A., Gazzard, B.G., Johnson, M.A., Orkin, C., Post, F., Ustianowski, A., Waters, L., Bailey, J., Benson, P., Bhatti, L., Brar, I., Bredeek, U.F., Brinson, C., Crofoot, G., Cunningham, D., DeJesus, E., Dietz, C., Dretler, R., Eron, J., Felizarta, F., Fichtenbaum, C., Gallant, J., Gathe, J., Hagins, D., Henn, S., Henry, W.K., Huhn, G., Jain, M., Lucasti, C., Martorell, C., McDonald, C., Mills, A., Morales-Ramirez, J., Mounzer, K., Nahass, R., Olivet, H., Osiyemi, O., Prelutsky, D., Ramgopal, M., Rashbaum, B., Richmond, G., Ruane, P., Scarsella, A., Scribner, A., Shalit, P., Shamblaw, D., Slim, J., Tashima, K., Voskuhl, G., Ward, D., Wilkin, A., de Vente, J., Eron, Joseph J., Orkin, Chloe, Cunningham, Douglas, Pulido, Federico, Post, Frank A., De Wit, Stéphane, Lathouwers, Erkki, Hufkens, Veerle, Jezorwski, John, Petrovic, Romana, Brown, Kimberley, Van Landuyt, Erika, and Opsomer, Magda

Published
2019
Full Text
View/download PDF

5. Changes in the Skin Microbiome Following Dermatological Procedures: A Scoping Review.

Author

Ellis, Jeremy R., Powell, Eron J., Tomasovic, Luke M., Marcheskie, Rachel L., Girish, Vishruth, Warman, Anmol, and Sivaloganathan, Darshan

Subjects
*SKIN diseases, *DERMATOLOGY, *DYSBIOSIS, *SKIN grafting, *PHOTODYNAMIC therapy
Abstract

The skin microbiome consists of bacteria, fungi, viruses, and mites, which play a crucial role in maintaining skin health and immune function. Imbalances in this microbial community, known as dysbiosis, are implicated in various dermatological conditions. While skincare products are known to influence the skin microbiome, the effects of dermatological procedures have not been extensively studied. Here, we perform a scoping review to outline the studies investigating the impacts of dermatological interventions on the skin microbiome. Phototherapy emerged as the most studied intervention, encompassing UV phototherapy, light therapy, laser therapy, and photodynamic therapy. Chemical interventions, such as chemical peels, micropigmentation, and debridement, have comparatively limited studies describing their impacts on the skin microbiome. To date, no studies have been done on a wide variety of common dermatological procedures such as cryotherapy, skin grafts, and dermabrasion, which may have stronger likelihoods of affecting the skin microbiome. This underscores the need for further research on the influences of dermatological procedures, especially chemical and physical interventions, on the skin microbiome. More comprehensive pre-clinical and clinical studies are essential not only for understanding the long-term consequences of these procedures, but also for optimizing patient outcomes in dermatological care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Author

Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, de Vente, J, De Wit, S, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y, Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Gathe, Joseph, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, and Opsomer, Magda

Published
2018
Full Text
View/download PDF

7. Sécurité et efficacité de Lenacapavir en association avec les bNAbs GS-5423 et GS-2872 administrés tous les 6 mois chez les personnes vivant avec le VIH

Author

Eron, J., primary, Little, S., additional, Crofoot, G., additional, Cook, P., additional, Ruane, P.J., additional, Jayaweera, D., additional, DeJesus, E., additional, Waldman, S.E., additional, Mehrotra, M.L., additional, VanderVeen, L., additional, Huang, H., additional, Collins, S., additional, Estrabaud, E., additional, Baeten, J., additional, and Caskey, M., additional

Published
2023
Full Text
View/download PDF

9. PP 4.14 – 00173 Antiretroviral therapy repairs CD4 T cell dysregulation in people living with HIV

Author

Sponaugle, A., primary, Weideman, A.M., additional, Ranek, J., additional, Archin, N., additional, Margolis, D.M., additional, Vincent, B.G., additional, Stanley, N., additional, Atassi, G., additional, Hudgens, M.G., additional, Eron, J., additional, Goonetilleke, N., additional, Kuritzkes, D., additional, Adimora, A., additional, and Andrade, A., additional

Published
2022
Full Text
View/download PDF

11. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection

Author

Moldt, B., Gunthard, H., Workowski, K., Little, S., Eron, J., Overton, E., Lehmann, C., Rokx, C., Kozal, M., Gandhi, R., Liu, H., Makadzange, T., Collins, S., Geleziunas, R., and Callebaut, C.

Subjects
Antiviral agents -- Patient outcomes, AIDS (Disease) -- Research, AIDS research, HIV infection -- Development and progression -- Care and treatment, Health
Abstract

Background: The persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART during primary HIV infection can limit the size and diversity of the viral [...]

Published
2021
Full Text
View/download PDF

13. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Author

Cahn, P, Madero, J, Arribas, J, Antinori, A, Ortiz, R, Clarke, A, Hung, C, Rockstroh, J, Girard, P, Sievers, J, Man, C, Currie, A, Underwood, M, Tenorio, A, Pappa, K, Wynne, B, Fettiplace, A, Gartland, M, Aboud, M, Smith, K, Cassetti, L, David, D, Figueras, L, Losso, M, Lopardo, G, Lupo, S, Porteiro, N, Sanchez, M, Bloch, M, Cooper, D, Finlayson, R, Kelleher, A, Koh, K, Lewis, D, Mcmahon, J, Moore, R, Roth, N, Shields, M, De Wit, S, Florence, E, Goffard, J, Demeester, R, Lacor, P, Vandercam, B, Vandekerckhove, L, Angel, J, Baril, J, Conway, B, De Pokomandy, A, Szabo, J, Walmsley, S, Bouchaud, O, Chidiac, C, Delobel, P, Goujard, C, Katlama, C, Molina, J, Pialoux, G, Philibert, P, Bogner, J, Esser, S, Krznaric, I, Lehmann, C, Spinner, C, Stellbrink, H, Stephan, C, Stoehr, A, Barchi, E, Caramello, P, Castelli, F, Cattelan, A, D'Arminio Monforte, A, Di Biagio, A, Di Perri, G, Gori, A, Maggiolo, F, Menzaghi, B, Migliorino, G, Mussini, C, Penco, G, Puoti, M, Rizzardini, G, Gulminetti, R, Lazzarin, A, Quirino, T, Sighinolfi, L, Viale, P, Amaya Tapia, G, Andrade Villanueva, J, Granados Reyes, E, Perez Rios, A, Santoscoy Gomez, M, Den Hollander, J, Rijnders, B, Hidalgo, J, Hercilla Vasquez, L, Illescas, L, Olczak, A, Mansinho, K, Correia Pacheco, P, Teofilo, E, Saraiva da Cunha, J, Sarmento e Castro, R, Serrao, R, Arbune, M, Jianu, C, Oprea, A, Preotescu, L, Prisacariu, L, Belonosova, E, Borodkina, O, Chernova, O, Gankina, N, Kizhlo, S, Kulagin, V, Kurina, N, Nagimova, F, Pokrovsky, V, Ryamova, E, Voronin, E, Yakovlev, A, Kaplan, R, Lee, S, Kim, S, Kim, W, Antela Lopez, A, Casado Osorio, J, Castano Carracedo, M, De Los Santos Gil, I, Estrada Perez, V, Falco Ferrer, V, Force, L, Galinda Puerto, M, Garcia Deltoro, M, Gatell, J, Goenaga Sanchez, M, Gonzalez Cordon, A, Knobel, H, Lopez Bernaldo de Quiros, J, Losa Garcia, J, Masia, M, Montero-Alsonso, M, Ocampo Hermida, A, Pasquau Liano, J, Portilla Sogorb, J, Pulido Ortega, F, Rivera Roman, A, Santos Fernandez, J, Torres Perea, R, Troya Garcia, J, Viciana Fernandez, P, Calmy, A, Hauser, C, Fehr, J, Cheng, S, Ko, W, Lin, H, Lu, P, Tseng, Y, Wang, N, Wong, W, Yang, C, Arduino, R, Benson, P, Berhe, M, Bredeek, F, Brinson, C, Campbell, T, Crofoot, G, Cunningham, D, Dejesus, E, Dretler, R, Eron, J, Fife, K, Fichtenbaum, C, Flamm, J, Goldstein, D, Gupta, S, Hagins, D, Hoffman-Terry, M, Jayaweera, D, Kinder, C, Klein, D, Mcdonald, C, Mills, A, Nahass, R, Osiyemi, O, Overton, E, Parks, D, Prelutsky, D, Ramgopal, M, Schrader, S, Sha, B, Simon, G, Sims, J, Skiest, D, Slim, J, Tashima, K, Thedinger, B, Gazzard, B, Fox, J, Johnson, M, Kegg, S, Khoo, S, Mazhude, C, Orkin, C, Schembri, G, Ustianowski, A, Cahn P., Madero J. S., Arribas J. R., Antinori A., Ortiz R., Clarke A. E., Hung C. -C., Rockstroh J. K., Girard P. -M., Sievers J., Man C., Currie A., Underwood M., Tenorio A. R., Pappa K., Wynne B., Fettiplace A., Gartland M., Aboud M., Smith K., Cassetti L., David D., Figueras L., Losso M., Lopardo G., Lupo S., Porteiro N., Sanchez M., Bloch M., Cooper D., Finlayson R., Kelleher A., Koh K., Lewis D., McMahon J., Moore R., Roth N., Shields M., De Wit S., Florence E., Goffard J. -C., Demeester R., Lacor P., Vandercam B., Vandekerckhove L., Angel J., Baril J. -G., Conway B., De Pokomandy A., Szabo J., Walmsley S., Bouchaud O., Chidiac C., Delobel P., Goujard C., Katlama C., Molina J. -M., Pialoux G., Philibert P., Bogner J., Esser S., Krznaric I., Lehmann C., Spinner C., Stellbrink H. -J., Stephan C., Stoehr A., Barchi E., Caramello P., Castelli F., Cattelan A. M., D'Arminio Monforte A., Di Biagio A., Di Perri G., Gori A., Maggiolo F., Menzaghi B., Migliorino G., Mussini C., Penco G., Puoti M., Rizzardini G., Gulminetti R., Lazzarin A., Quirino T., Sighinolfi L., Viale P., Amaya Tapia G., Andrade Villanueva J., Granados Reyes E. R., Perez Rios A., Santoscoy Gomez M., Den Hollander J., Rijnders B., Hidalgo J. A., Hercilla Vasquez L., Illescas L., Olczak A., Mansinho K., Correia Pacheco P. P., Teofilo E., Saraiva da Cunha J., Sarmento e Castro R., Serrao R., Arbune M., Jianu C., Oprea A., Preotescu L., Prisacariu L. -J., Belonosova E., Borodkina O., Chernova O., Gankina N., Kizhlo S., Kulagin V., Kurina N., Nagimova F., Pokrovsky V., Ryamova E., Voronin E., Yakovlev A., Kaplan R., Lee S. H., Kim S. -W., Kim S. -I., Kim W. J., Antela Lopez A., Casado Osorio J. L., Castano Carracedo M. A., De Los Santos Gil I., Estrada Perez V., Falco Ferrer V., Force L., Galinda Puerto M. J., Garcia Deltoro M., Gatell J. M., Goenaga Sanchez M. A., Gonzalez Cordon A., Knobel H., Lopez Bernaldo de Quiros J. C., Losa Garcia J. E., Masia M., Montero-Alsonso M., Ocampo Hermida A., Pasquau Liano J., Portilla Sogorb J., Pulido Ortega F., Rivera Roman A., Santos Fernandez J. R., Torres Perea R., Troya Garcia J., Viciana Fernandez P., Calmy A., Hauser C., Fehr J., Cheng S. -H., Ko W. -C., Lin H. -H., Lu P. -L., Tseng Y. -T., Wang N. -C., Wong W. -W., Yang C. -J., Arduino R., Benson P., Berhe M., Bredeek F., Brinson C., Campbell T., Crofoot G., Cunningham D., DeJesus E., Dretler R., Eron J., Fife K., Fichtenbaum C., Flamm J., Goldstein D., Gupta S., Hagins D., Hoffman-Terry M., Jayaweera D., Kinder C., Klein D., McDonald C., Mills A., Nahass R., Osiyemi O., Overton E., Parks D., Prelutsky D., Ramgopal M., Schrader S., Sha B., Simon G., Sims J., Skiest D., Slim J., Tashima K., Thedinger B., Gazzard B., Fox J., Johnson M., Kegg S., Khoo S., Mazhude C., Orkin C., Schembri G., Ustianowski A., Cahn, P, Madero, J, Arribas, J, Antinori, A, Ortiz, R, Clarke, A, Hung, C, Rockstroh, J, Girard, P, Sievers, J, Man, C, Currie, A, Underwood, M, Tenorio, A, Pappa, K, Wynne, B, Fettiplace, A, Gartland, M, Aboud, M, Smith, K, Cassetti, L, David, D, Figueras, L, Losso, M, Lopardo, G, Lupo, S, Porteiro, N, Sanchez, M, Bloch, M, Cooper, D, Finlayson, R, Kelleher, A, Koh, K, Lewis, D, Mcmahon, J, Moore, R, Roth, N, Shields, M, De Wit, S, Florence, E, Goffard, J, Demeester, R, Lacor, P, Vandercam, B, Vandekerckhove, L, Angel, J, Baril, J, Conway, B, De Pokomandy, A, Szabo, J, Walmsley, S, Bouchaud, O, Chidiac, C, Delobel, P, Goujard, C, Katlama, C, Molina, J, Pialoux, G, Philibert, P, Bogner, J, Esser, S, Krznaric, I, Lehmann, C, Spinner, C, Stellbrink, H, Stephan, C, Stoehr, A, Barchi, E, Caramello, P, Castelli, F, Cattelan, A, D'Arminio Monforte, A, Di Biagio, A, Di Perri, G, Gori, A, Maggiolo, F, Menzaghi, B, Migliorino, G, Mussini, C, Penco, G, Puoti, M, Rizzardini, G, Gulminetti, R, Lazzarin, A, Quirino, T, Sighinolfi, L, Viale, P, Amaya Tapia, G, Andrade Villanueva, J, Granados Reyes, E, Perez Rios, A, Santoscoy Gomez, M, Den Hollander, J, Rijnders, B, Hidalgo, J, Hercilla Vasquez, L, Illescas, L, Olczak, A, Mansinho, K, Correia Pacheco, P, Teofilo, E, Saraiva da Cunha, J, Sarmento e Castro, R, Serrao, R, Arbune, M, Jianu, C, Oprea, A, Preotescu, L, Prisacariu, L, Belonosova, E, Borodkina, O, Chernova, O, Gankina, N, Kizhlo, S, Kulagin, V, Kurina, N, Nagimova, F, Pokrovsky, V, Ryamova, E, Voronin, E, Yakovlev, A, Kaplan, R, Lee, S, Kim, S, Kim, W, Antela Lopez, A, Casado Osorio, J, Castano Carracedo, M, De Los Santos Gil, I, Estrada Perez, V, Falco Ferrer, V, Force, L, Galinda Puerto, M, Garcia Deltoro, M, Gatell, J, Goenaga Sanchez, M, Gonzalez Cordon, A, Knobel, H, Lopez Bernaldo de Quiros, J, Losa Garcia, J, Masia, M, Montero-Alsonso, M, Ocampo Hermida, A, Pasquau Liano, J, Portilla Sogorb, J, Pulido Ortega, F, Rivera Roman, A, Santos Fernandez, J, Torres Perea, R, Troya Garcia, J, Viciana Fernandez, P, Calmy, A, Hauser, C, Fehr, J, Cheng, S, Ko, W, Lin, H, Lu, P, Tseng, Y, Wang, N, Wong, W, Yang, C, Arduino, R, Benson, P, Berhe, M, Bredeek, F, Brinson, C, Campbell, T, Crofoot, G, Cunningham, D, Dejesus, E, Dretler, R, Eron, J, Fife, K, Fichtenbaum, C, Flamm, J, Goldstein, D, Gupta, S, Hagins, D, Hoffman-Terry, M, Jayaweera, D, Kinder, C, Klein, D, Mcdonald, C, Mills, A, Nahass, R, Osiyemi, O, Overton, E, Parks, D, Prelutsky, D, Ramgopal, M, Schrader, S, Sha, B, Simon, G, Sims, J, Skiest, D, Slim, J, Tashima, K, Thedinger, B, Gazzard, B, Fox, J, Johnson, M, Kegg, S, Khoo, S, Mazhude, C, Orkin, C, Schembri, G, Ustianowski, A, Cahn P., Madero J. S., Arribas J. R., Antinori A., Ortiz R., Clarke A. E., Hung C. -C., Rockstroh J. K., Girard P. -M., Sievers J., Man C., Currie A., Underwood M., Tenorio A. R., Pappa K., Wynne B., Fettiplace A., Gartland M., Aboud M., Smith K., Cassetti L., David D., Figueras L., Losso M., Lopardo G., Lupo S., Porteiro N., Sanchez M., Bloch M., Cooper D., Finlayson R., Kelleher A., Koh K., Lewis D., McMahon J., Moore R., Roth N., Shields M., De Wit S., Florence E., Goffard J. -C., Demeester R., Lacor P., Vandercam B., Vandekerckhove L., Angel J., Baril J. -G., Conway B., De Pokomandy A., Szabo J., Walmsley S., Bouchaud O., Chidiac C., Delobel P., Goujard C., Katlama C., Molina J. -M., Pialoux G., Philibert P., Bogner J., Esser S., Krznaric I., Lehmann C., Spinner C., Stellbrink H. -J., Stephan C., Stoehr A., Barchi E., Caramello P., Castelli F., Cattelan A. M., D'Arminio Monforte A., Di Biagio A., Di Perri G., Gori A., Maggiolo F., Menzaghi B., Migliorino G., Mussini C., Penco G., Puoti M., Rizzardini G., Gulminetti R., Lazzarin A., Quirino T., Sighinolfi L., Viale P., Amaya Tapia G., Andrade Villanueva J., Granados Reyes E. R., Perez Rios A., Santoscoy Gomez M., Den Hollander J., Rijnders B., Hidalgo J. A., Hercilla Vasquez L., Illescas L., Olczak A., Mansinho K., Correia Pacheco P. P., Teofilo E., Saraiva da Cunha J., Sarmento e Castro R., Serrao R., Arbune M., Jianu C., Oprea A., Preotescu L., Prisacariu L. -J., Belonosova E., Borodkina O., Chernova O., Gankina N., Kizhlo S., Kulagin V., Kurina N., Nagimova F., Pokrovsky V., Ryamova E., Voronin E., Yakovlev A., Kaplan R., Lee S. H., Kim S. -W., Kim S. -I., Kim W. J., Antela Lopez A., Casado Osorio J. L., Castano Carracedo M. A., De Los Santos Gil I., Estrada Perez V., Falco Ferrer V., Force L., Galinda Puerto M. J., Garcia Deltoro M., Gatell J. M., Goenaga Sanchez M. A., Gonzalez Cordon A., Knobel H., Lopez Bernaldo de Quiros J. C., Losa Garcia J. E., Masia M., Montero-Alsonso M., Ocampo Hermida A., Pasquau Liano J., Portilla Sogorb J., Pulido Ortega F., Rivera Roman A., Santos Fernandez J. R., Torres Perea R., Troya Garcia J., Viciana Fernandez P., Calmy A., Hauser C., Fehr J., Cheng S. -H., Ko W. -C., Lin H. -H., Lu P. -L., Tseng Y. -T., Wang N. -C., Wong W. -W., Yang C. -J., Arduino R., Benson P., Berhe M., Bredeek F., Brinson C., Campbell T., Crofoot G., Cunningham D., DeJesus E., Dretler R., Eron J., Fife K., Fichtenbaum C., Flamm J., Goldstein D., Gupta S., Hagins D., Hoffman-Terry M., Jayaweera D., Kinder C., Klein D., McDonald C., Mills A., Nahass R., Osiyemi O., Overton E., Parks D., Prelutsky D., Ramgopal M., Schrader S., Sha B., Simon G., Sims J., Skiest D., Slim J., Tashima K., Thedinger B., Gazzard B., Fox J., Johnson M., Kegg S., Khoo S., Mazhude C., Orkin C., Schembri G., and Ustianowski A.

Abstract

Background: Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen for the treatment of HIV-1 infection in ART-naive adults. Methods: We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and GEMINI-2. Both studies were done at 192 centres in 21 countries. We included participants (≥18 years) with HIV-1 infection and a screening HIV-1 RNA of 500 000 copies per mL or less, and who were naive to ART. We randomly assigned participants (1:1) to receive a once-daily two-drug regimen of dolutegravir (50 mg) plus lamivudine (300 mg) or a once-daily three-drug regimen of dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Both drug regimens were administered orally. We masked participants and investigators to treatment assignment: dolutegravir was administered as single-entity tablets (similar to its commercial formulation, except with a different film colour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets were over-encapsulated to visually match each other. Primary endpoint was the proportion of participants with HIV-1 RNA of less than 50 copies per mL at week 48 in the intention-to-treat-exposed population, using the Snapshot algorithm and a non-inferiority margin of −10%. Safety analyses were done on the safety population. GEMINI-1 and GEMINI-2 are registered with ClinicalTrials.gov, numbers NCT02831673 and NCT02831764, respectively. Findings: Between July 18, 2016, and March 31, 2017, 1441 participants across both studies were randomly assigned to receive either the two-drug regimen (n=719) or three-drug regimen (n=722). At week 48 in the GEMINI-1 intention-to-treat-exposed population, 320 (90%) of 356 participants receiving the two-drug regimen and 332

Published
2019

14. Additional file 2 of Correlates of psychological intimate partner violence with HIV care outcomes on patients in HIV care

Author

Fredericksen, R. J., Nance, R. M., Whitney, B. M., Harding, B. N., Fitzsimmons, E., Del Rio, C., Eron, J., Feaster, D. J., Kalokhe, A. S., Mathews, W. C., Mayer, K. H., Metsch, L. R., Mugavero, M. J., Potter, J., O’Cleirigh, C., Napravnik, S., Rodriguez, B., Ruderman, S., JAC, Delaney, and Crane, H. M.

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2021
Full Text
View/download PDF

15. Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma

Author

Sellers, S.A., Eron, J., Tompkins, K., Parr, J.B., Rubiano, C., Bramson, B., and Schranz, A.J.

Subjects
respiratory tract diseases
Abstract

We present a case of a critically ill patient with coronavirus disease 2019 (COVID-19) found to have acquired immune deficiency syndrome and Pneumocystis jirovecii pneumonia (PCP). Coronavirus disease 2019 and PCP co-occurrence is increasingly reported and may complicate diagnostic and therapeutic strategies. Patients with severe COVID-19 should be screened for underlying immunocompromise and coinfections should be considered.

Published
2021
Full Text
View/download PDF

16. The Authors Reply

Author

Crane, H. M., Heckbert, S. R., Drozd, D. R., Budoff, M. J., Delaney, J. A. C., Rodriguez, C., Paramsothy, P., Lober, W. B., Burkholder, G., Willig, J. H., Mugavero, M. J., Mathews, W. C., Crane, P. K., Moore, R. D., Napravnik, S., Eron, J. J., Hunt, P., Geng, E., Hsue, P., Barnes, G. S., McReynolds, J., Peter, I., Grunfeld, C., Saag, M. S., and Kitahata, M. M.

Published
2014
Full Text
View/download PDF

17. Lessons Learned From the Design and Implementation of Myocardial Infarction Adjudication Tailored for HIV Clinical Cohorts

Author

Crane, H. M., Heckbert, S. R., Drozd, D. R., Budoff, M. J., Delaney, J. A. C., Rodriguez, C., Paramsothy, P., Lober, W. B., Burkholder, G., Willig, J. H., Mugavero, M. J., Mathews, W. C., Crane, P. K., Moore, R. D., Napravnik, S., Eron, J. J., Hunt, P., Geng, E., Hsue, P., Barnes, G. S., McReynolds, J., Peter, I., Grunfeld, C., Saag, M. S., and Kitahata, M. M.

Published
2014
Full Text
View/download PDF

18. Profiling the HIV epidemic with recency of infection instead of recency of diagnosis: 2 years of experience in North Carolina, USA

Author

Zhou, S., Sizemore, S., Moesers, M., Zimmerman, S., Samoff, E., Mobley, V., Frost, S., Cressman, A., Eron, J., Clark, M., Jones, C., Cohen, M., Nelson, J., Swanstrom, R., and Dennis, A.

Subjects
Nucleotide sequencing -- Usage, Epidemics -- Statistics -- United States, DNA sequencing -- Usage, Molecular diagnostic techniques -- Usage, HIV infection -- Statistics -- Diagnosis -- Genetic aspects, Health
Abstract

Background: The identification of recent (incident) HIV infections among people who are initially diagnosed for the first time is critical to HIV prevention. We developed a Multiplexed Primer ID-Next Gen Sequencing (MPID-NGS) approach to identify recent infection by measuring the intra-host viral diversity over multiple regions of the HIV genome. We examined the field implementations of MPID-NGS to identify recent infection and drug resistance mutations (DRMs) among persons with new HIV diagnoses reported by the North Carolina State Laboratory of Public Health in 2018 and 2019. Methods: The MPID-NGS libraries were constructed for protease (PR), partial reverse transcriptase (RT), integrase (IN), and the V1 to V3 region of the env gene using remnant serological diagnostic tests. New diagnoses were restricted to sera collected within 30 days of HIV diagnosis dates. The MiSeq platform was used for sequencing. The TCS-DR pipeline was used for bioinformatics analysis and to identify DRMs. Recent infection was defined as infection Results: A total of 515 persons with new diagnoses from 2018 to 2019 were successfully sequenced. Overall, 202 (39%) had recent infection, 241 (47%) were chronically infected, and 72 (14%) had indeterminate recency at time of diagnosis. We detected a greater percentage of recent infections in 2019 than 2018 (44% vs. 35%, p = 0.06). By comparing the characteristics of recent versus chronic infection at diagnosis, we found that young people were more likely to be diagnosed in the recent infection stage (p < 0.01), and individuals diagnosed with recent infection were more likely to be in active transmission clusters than those with chronic infection (p < 0.01). K103N was the most commonly seen DRM (approximately 10%) while other clinically significant DRMs were rarely seen. Conclusions: We demonstrate an all-in-one platform to monitor HIV-1 recency, DRMs, and phylogenetically linked transmission clusters in near real-time. We believe this approach has the potential to be a useful tool as part of public health efforts to reduce new infections by monitoring the percentage of recency among new HIV diagnoses and providing opportunity to interrupt transmission within clusters., OA02.01 S. Zhou (1); S. Sizemore (2); M. Moesers (1); S. Zimmerman (3); E. Samoff (3); V. Mobley (3); S. Frost (4); A. Cressman (5); J. Eron (2); M. Clark [...]

Published
2021
Full Text
View/download PDF

19. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Author

Lathouwers E, Wong E, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine E, Van Landuyt E, Opsomer M, De Meyer S, De Wit S, Florence E, Vandekerckhove L, Vandercam B, Brunetta J, Klein M, Murphy D, Rachlis A, Walmsley S, Ajana F, Cotte L, Girard P, Katlama C, Molina J, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Arasteh K, Bickel M, Bogner J, Esser S, Faetkenheuer G, Jessen H, Kern W, Rockstroh J, Spinner C, Stellbrink H, Stoehr A, Antinori A, Castelli F, Chirianni A, De Luca A, Di Biagio A, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mussini C, Garlicki A, Gasiorowski J, Halota W, Horban A, Parczewski M, Piekarska A, Belonosova E, Chernova O, Dushkina N, Kulagin V, Ryamova E, Shuldyakov A, Sizova N, Tsybakova O, Voronin E, Yakovlev A, Antela A, Arribas J, Berenguer J, Casado J, Estrada V, Galindo M, Del Toro M, Gatell J, Gorgolas M, Gutierrez F, Gutierrez M, Negredo E, Pineda J, Podzamczer D, Sogorb J, Rivero A, Rubio R, Viciana P, De Los Santos I, Clarke A, Gazzard B, Johnson M, Orkin C, Reeves I, Waters L, Benson P, Bhatti L, Bredeek F, Crofoot G, Cunningham D, DeJesus E, Eron J, Felizarta F, Franco R, Gallant J, Hagins D, Henry K, Jayaweera D, Lucasti C, Martorell C, McDonald C, McGowan J, Mills A, Morales-Ramirez J, Prelutsky D, Ramgopal M, Rashbaum B, Ruane P, Slim J, Wilkin A, deVente J, Moutschen M, Van Wijngaerden E, Vekerckhove L, Vercam B, Conway B, Shafran S, AMBER Study Grp, and EMERALD Study Grp

Subjects
resistance, deep sequencing, TAF, efficacy, virus diseases, darunavir, cobicistat, archived RAMs, emtricitabine, single-tablet regimen
Abstract

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) >= 400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL = 3 thymidine analog-associated mutations (24% not fully susceptible to tenofovir) detected at screening. All achieved VL

Published
2020

23. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study

Author

Harding, B. N., primary, Whitney, B. M., additional, Nance, R. M., additional, Ruderman, S. A., additional, Crane, H. M., additional, Burkholder, G., additional, Moore, R. D., additional, Mathews, W. C., additional, Eron, J. J., additional, Hunt, P. W., additional, Volberding, P., additional, Rodriguez, B., additional, Mayer, K. H., additional, Saag, M. S., additional, Kitahata, M. M., additional, Heckbert, S. R., additional, and Delaney, J. A. C., additional

Published
2020
Full Text
View/download PDF

24. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials: report of a consensus meeting

Author

Miller, V., Pantaleo, G., Tiemessen, C.T., Kuritzkes, D., Schacker, T., Stephenson, K., Julg, B., Sugarman, J., Colby, D.J., Sogaard, O.S., Dee, L., Ananworanich, J., Nixon, D.F., Michael, N.L., Johnston, R., Dube, K., Palm, D., Goulder, P., Jefferys, R., Tressler, R., Dawson, L., Likhitwonnawut, U., Spudich, S., Tebas, P., Eron, J., Robb, M.L., Frater, J., Weiss, C.D., Sheikh, V., Barouch, D.H., van Lunzen, J., Peay, H., Geleziunas, R., Zheng, L., Deeks, S.G., Bar, K., Hanna, G.J., Martinez-Picado, J., Walker, B.D., Salzwedel, K., Mellors, J.W., Dong, K.L., Li, J.Z., Gandhi, R.T., Salzwedel, J., Taylor, J., Caskey, M., Persaud, D., and Montaner, L.J.

Abstract

Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.

Published
2019
Full Text
View/download PDF

25. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Author

Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M, and EMERALD study group

Published
2019

26. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Author

Lathouwers, Erkki, Wong, Eric Y, Brown, Kimberley, Baugh, Bryan, Ghys, Anne, Jezorwski, John, Mohsine, El Ghazi, Van Landuyt, Erika, Opsomer, Magda, De Meyer, Sandra, De Wit, S, Florence, E, Vandekerckhove, L, Vandercam, B, Brunetta, J, Klein, M, Murphy, D, Rachlis, A, Walmsley, S, Ajana, F, Cotte, L, Girard, P-M, Katlama, C, Molina, J-M, Poizot-Martin, I, Raffi, F, Rey, D, Reynes, J, Teicher, E, Yazdanpanah, Y, Arasteh, K, Bickel, M, Bogner, J, Esser, S, Faetkenheuer, G, Jessen, H, Kern, W, Rockstroh, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Antinori, A, Castelli, F, Chirianni, A, De Luca, A, Di Biagio, A, Galli, M, Lazzarin, A, Maggiolo, F, Maserati, R, Mussini, C, Garlicki, A, Gasiorowski, J, Halota, W, Horban, A, Parczewski, M, Piekarska, A, Belonosova, E, Chernova, O, Dushkina, N, Kulagin, V, Ryamova, E, Shuldyakov, A, Sizova, N, Tsybakova, O, Voronin, E, Yakovlev, A, Antela, A, Arribas, JR, Berenguer, J, Casado, J, Estrada, V, Galindo, MJ, Garcia Del Toro, M, Gatell, JM, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Negredo, E, Pineda, JA, Podzamczer, D, Portilla Sogorb, J, Rivero, A, Rubio, R, Viciana, P, De Los Santos, I, Clarke, A, Gazzard, BG, Johnson, MA, Orkin, C, Reeves, I, Waters, L, Benson, P, Bhatti, L, Bredeek, F, Crofoot, G, Cunningham, D, DeJesus, E, Eron, J, Felizarta, F, Franco, R, Gallant, J, Hagins, D, Henry, K, Jayaweera, D, Lucasti, C, Martorell, C, McDonald, C, McGowan, J, Mills, A, Morales-Ramirez, J, Prelutsky, D, Ramgopal, M, Rashbaum, B, Ruane, P, Slim, J, Wilkin, A, deVente, J, Moutschen, M, Van Wijngaerden, E, Vekerckhove, L, Vercam, B, Conway, B, Shafran, S, Janssen Pharmaceutica [Beerse], Janssen Pharmaceutical Research and Development Titusville, AMBER and EMERALD Study Groups: S De Wit, E Florence, L Vandekerckhove, B Vandercam, J Brunetta, M Klein, D Murphy, A Rachlis, S Walmsley, F Ajana, L Cotte, P-M Girard, C Katlama, J-M Molina, I Poizot-Martin, F Raffi, D Rey, J Reynes, E Teicher, Y Yazdanpanah, K Arastéh, M Bickel, J Bogner, S Esser, G Faetkenheuer, H Jessen, W Kern, J Rockstroh, C Spinner, H-J Stellbrink, A Stoehr, A Antinori, F Castelli, A Chirianni, A De Luca, A Di Biagio, M Galli, A Lazzarin, F Maggiolo, R Maserati, C Mussini, A Garlicki, J Gasiorowski, W Halota, A Horban, M Parczewski, A Piekarska, E Belonosova, O Chernova, N Dushkina, V Kulagin, E Ryamova, A Shuldyakov, N Sizova, O Tsybakova, E Voronin, A Yakovlev, A Antela, J R Arribas, J Berenguer, J Casado, V Estrada, M J Galindo, M Garcia Del Toro, J M Gatell, M Gorgolas, F Gutierrez, Mdm Gutierrez, E Negredo, J A Pineda, D Podzamczer, J Portilla Sogorb, A Rivero, R Rubio, P Viciana, I De Los Santos, A Clarke, B G Gazzard, M A Johnson, C Orkin, I Reeves, L Waters, P Benson, L Bhatti, F Bredeek, G Crofoot, D Cunningham, E DeJesus, J Eron, F Felizarta, R Franco, J Gallant, D Hagins, K Henry, D Jayaweera, C Lucasti, C Martorell, C McDonald, J McGowan, A Mills, J Morales-Ramirez, D Prelutsky, M Ramgopal, B Rashbaum, P Ruane, J Slim, A Wilkin, J deVente, S De Wit, E Florence, M Moutschen, E Van Wijngaerden, L Vandekerckhove, B Vandercam, J Brunetta, B Conway, M Klein, D Murphy, A Rachlis, S Shafran, S Walmsley, F Ajana, L Cotte, P-M Girard, C Katlama, J-M Molina, I Poizot-Martin, F Raffi, D Rey, J Reynes, E Teicher, Y Yazdanpanah, J Gasiorowski, W Halota, A Horban, A Piekarska, A Witor, J R Arribas, I Perez-Valero, J Berenguer, J Casado, J M Gatell, F Gutierrez, M J Galindo, Mdm Gutierrez, J A Iribarren, H Knobel, E Negredo, J A Pineda, D Podzamczer, J Portilla Sogorb, F Pulido, C Ricart, A Rivero, I Santos Gil, A Blaxhult, L Flamholc, M Gisslèn, A Thalme, J Fehr, A Rauch, M Stoeckle, A Clarke, B G Gazzard, M A Johnson, C Orkin, F Post, A Ustianowski, L Waters, J Bailey, P Benson, L Bhatti, I Brar, U F Bredeek, C Brinson, G Crofoot, D Cunningham, E DeJesus, C Dietz, R Dretler, J Eron, F Felizarta, C Fichtenbaum, J Gallant, J Gathe, D Hagins, S Henn, K W Henry, G Huhn, M Jain, C Lucasti, C Martorell, C McDonald, A Mills, J Morales-Ramirez, K Mounzer, R Nahass, H Olivet, O Osiyemi, D Prelutsky, M Ramgopal, B Rashbaum, G Richmond, P Ruane, A Scarsella, A Scribner, P Shalit, D Shamblaw, J Slim, K Tashima, G Voskuhl, D Ward, A Wilkin, J de Vente, and Malbec, Odile

Subjects
0301 basic medicine, [SDV]Life Sciences [q-bio], efficacy, Human immunodeficiency virus (HIV), HIV Infections, darunavir, medicine.disease_cause, VIRALLY SUPPRESSED ADULTS, PLUS LAMIVUDINE, DOUBLE-BLIND, 0302 clinical medicine, INFECTION, Medicine and Health Sciences, Emtricitabine, 030212 general & internal medicine, Darunavir, Emtricitabine tenofovir alafenamide, Alanine, Cobicistat, Single tablet regimen, virus diseases, Viral Load, OPEN-LABEL, 3. Good health, [SDV] Life Sciences [q-bio], Drug Combinations, Infectious Diseases, NON-INFERIORITY, INITIAL TREATMENT, Reverse Transcriptase Inhibitors, Life Sciences & Biomedicine, Tablets, medicine.drug, Adult, TENOFOVIR DISOPROXIL FUMARATE, Anti-HIV Agents, Darunavir/Cobicistat, Immunology, archived RAMs, Tenofovir alafenamide, Drug Administration Schedule, single-tablet regimen, resistance, 03 medical and health sciences, deep sequencing, Virology, Drug Resistance, Viral, medicine, darunavir/cobicistat/emtricitabine/TAF, Humans, Clinical Trials/Clinical Studies, Tenofovir, emtricitabine, DRUG-RESISTANCE, Science & Technology, TREATMENT-NAIVE PATIENTS, business.industry, Adenine, cobicistat, 030104 developmental biology, TAF, HIV-1, business
Abstract

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) ≥400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL

Published
2019
Full Text
View/download PDF

29. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author

Rohner E., Butikofer L., Schmidlin K., Sengayi M., Maskew M., Giddy J., Garone D., Moore R. D., D'Souza G., Goedert J. J., Achenbach C., Gill M. J., Kitahata M. M., Patel P., Silverberg M. J., Castilho J., McGowan C., Chen Y. -M. A., Law M., Taylor N., Paparizos V., Bonnet F., Verbon A., Fatkenheuer G., Post F. A., Sabin C., Mocroft A., Le Moing V., Dronda F., Obel N., Grabar S., Spagnuolo V., Antinori A., Quiros-Roldan E., Mussini C., Miro J. M., Meyer L., Hasse B., Konopnicki D., Roca B., Barger D., Raben D., Clifford G. M., Franceschi S., Brockmeyer N., Chakraborty R., Egger M., Bohlius J., Judd A., Zangerle R., Touloumi G., Warszawski J., Dabis F., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Thorne C., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A. D., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., De Wit S., Costagliola D., D'Arminio-Monforte A., Chene G., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., Torti C., Van Der Valk M., Tanser F., Vinikoor M., MacEte E., Wood R., Stinson K., Fatti G., Phiri S., Chimbetete C., Malisita K., Eley B., Fritz C., Hobbins M., Kamenova K., Fox M., Prozesky H., Technau K., Sawry S., Benson C. A., Bosch R. J., Kirk G. D., Boswell S., Mayer K. H., Grasso C., Hogg R. S., Harrigan P. R., Montaner J. S. G., Yip B., Zhu J., Salters K., Gabler K., Buchacz K., Brooks J. T., Gebo K. A., Carey J. T., Rodriguez B., Horberg M. A., Thorne J. E., Rabkin C., Margolick J. B., Jacobson L. P., Klein M. B., Rourke S. B., Rachlis A. R., Cupido P., Hunter-Mellado R. F., Mayor A. M., Deeks S. G., Martin J. N., Saag M. S., Mugavero M. J., Willig J., Eron J. J., Napravnik S., Crane H. M., Drozd D. R., Haas D., Rebeiro P., Turner M., Bebawy S., Rogers B., Justice A. C., Dubrow R., Fiellin D., Gange S. J., Anastos K., Althoff K. N., McKaig R. G., Freeman A. M., Lent C., Van Rompaey S. E., Morton L., McReynolds J., Lober W. B., Abraham A. G., Lau B., Zhang J., Jing J., Modur S., Wong C., Hogan B., Desir F., Liu B., You B., Cahn P., Cesar C., Fink V., Sued O., Dell'Isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., De Boni R., Wagner S. C., Friedman R., Moreira R., Pinto J., Ferreira F., Maia M., De Menezes Succi R. C., MacHado D. M., De Fatima Barbosa Gouvea A., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Rouzier V., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Mejia F., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Duda S. N., Maruri F., Vansell H., Ly P. S., Khol V., Zhang F. J., Zhao H. X., Han N., Lee M. P., Li P. C. K., Lam W., Chan Y. T., Kumarasamy N., Saghayam S., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Merati T. P., Wirawan D. N., Yuliana F., Yunihastuti E., Imran D., Widhani A., Tanuma J., Oka S., Nishijima T., Choi J. Y., Na S., Kim J. M., Sim B. L. H., Gani Y. M., David R., Kamarulzaman A., Syed Omar S. F., Ponnampalavanar S., Azwa I., Ditangco R., Uy E., Bantique R., Wong W. W., Ku W. W., Wu P. C., Ng O. T., Lim P. L., Lee L. S., Ohnmar P. S., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Sungkanuparph S., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Kotarathititum W., Praparattanapan J., Kantipong P., Kambua P., Ratanasuwan W., Sriondee R., Nguyen K. V., Bui H. V., Nguyen D. T. H., Nguyen D. T., Cuong D. D., An N. V., Luan N. T., Sohn A. H., Ross J. L., Petersen B., Cooper D. A., Law M. G., Jiamsakul A., Boettiger D. C., Ellis D., Bloch M., Agrawal S., Vincent T., Allen D., Smith D., Rankin A., Baker D., Templeton D. J., Jackson E., McCallum K., Ryder N., Sweeney G., Cooper D., Carr A., MacRae K., Hesse K., Finlayson R., Gupta S., Langton-Lockton J., Shakeshaft J., Brown K., Idle S., Arvela N., Varma R., Lu H., Couldwell D., Eswarappa S., Smith D. E., Furner V., Cabrera G., Fernando S., Cogle A., Lawrence C., Mulhall B., Boyd M., Petoumenos K., Puhr R., Huang R., Han A., Gunathilake M., Payne R., O'Sullivan M., Croydon A., Russell D., Cashman C., Roberts C., Sowden D., Taing K., Marshall P., Orth D., Youds D., Rowling D., Latch N., Warzywoda E., Dickson B., Donohue W., Moore R., Edwards S., Boyd S., Roth N. J., Lau H., Read T., Silvers J., Zeng W., Hoy J., Watson K., Bryant M., Price S., Woolley I., Giles M., Korman T., Williams J., Nolan D., Allen A., Guelfi G., Mills G., Wharry C., Raymond N., Bargh K., Templeton D., Medical Microbiology & Infectious Diseases, Global Health, Infectious diseases, APH - Aging & Later Life, AII - Infectious diseases, APH - Global Health, Graduate School, APH - Digital Health, APH - Personalized Medicine, Bohlius, Julia, Cohere In, Eurocoord, Castagna, Antonella, Rohner, E, Butikofer, L, Schmidlin, K, Sengayi, M, Maskew, M, Giddy, J, Garone, D, Moore, R, D'Souza, G, Goedert, J, Achenbach, C, Gill, M, Kitahata, M, Patel, P, Silverberg, M, Castilho, J, Mcgowan, C, Chen, Y, Law, M, Taylor, N, Paparizos, V, Bonnet, F, Verbon, A, Fatkenheuer, G, Post, F, Sabin, C, Mocroft, A, Le Moing, V, Dronda, F, Obel, N, Grabar, S, Spagnuolo, V, Antinori, A, Quiros-Roldan, E, Mussini, C, Miro, J, Meyer, L, Hasse, B, Konopnicki, D, Roca, B, Barger, D, Raben, D, Clifford, G, Franceschi, S, Brockmeyer, N, Chakraborty, R, Egger, M, Bohlius, J, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, De Wit, S, Costagliola, D, D'Arminio-Monforte, A, Chene, G, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Torti, C, Van Der Valk, M, Tanser, F, Vinikoor, M, Macete, E, Wood, R, Stinson, K, Fatti, G, Phiri, S, Chimbetete, C, Malisita, K, Eley, B, Fritz, C, Hobbins, M, Kamenova, K, Fox, M, Prozesky, H, Technau, K, Sawry, S, Benson, C, Bosch, R, Kirk, G, Boswell, S, Mayer, K, Grasso, C, Hogg, R, Harrigan, P, Montaner, J, Yip, B, Zhu, J, Salters, K, Gabler, K, Buchacz, K, Brooks, J, Gebo, K, Carey, J, Rodriguez, B, Horberg, M, Thorne, J, Rabkin, C, Margolick, J, Jacobson, L, Klein, M, Rourke, S, Rachlis, A, Cupido, P, Hunter-Mellado, R, Mayor, A, Deeks, S, Martin, J, Saag, M, Mugavero, M, Willig, J, Eron, J, Napravnik, S, Crane, H, Drozd, D, Haas, D, Rebeiro, P, Turner, M, Bebawy, S, Rogers, B, Justice, A, Dubrow, R, Fiellin, D, Gange, S, Anastos, K, Althoff, K, Mckaig, R, Freeman, A, Lent, C, Van Rompaey, S, Morton, L, Mcreynolds, J, Lober, W, Abraham, A, Lau, B, Zhang, J, Jing, J, Modur, S, Wong, C, Hogan, B, Desir, F, Liu, B, You, B, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, De Boni, R, Wagner, S, Friedman, R, Moreira, R, Pinto, J, Ferreira, F, Maia, M, De Menezes Succi, R, Machado, D, De Fatima Barbosa Gouvea, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Rouzier, V, Marcelin, A, Perodin, C, Luque, M, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Mejia, F, Carriquiry, G, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Giganti, M, Duda, S, Maruri, F, Vansell, H, Ly, P, Khol, V, Zhang, F, Zhao, H, Han, N, Lee, M, Li, P, Lam, W, Chan, Y, Kumarasamy, N, Saghayam, S, Ezhilarasi, C, Pujari, S, Joshi, K, Gaikwad, S, Chitalikar, A, Merati, T, Wirawan, D, Yuliana, F, Yunihastuti, E, Imran, D, Widhani, A, Tanuma, J, Oka, S, Nishijima, T, Choi, J, Na, S, Kim, J, Sim, B, Gani, Y, David, R, Kamarulzaman, A, Syed Omar, S, Ponnampalavanar, S, Azwa, I, Ditangco, R, Uy, E, Bantique, R, Wong, W, Ku, W, Wu, P, Ng, O, Lim, P, Lee, L, Ohnmar, P, Avihingsanon, A, Gatechompol, S, Phanuphak, P, Phadungphon, C, Kiertiburanakul, S, Sungkanuparph, S, Chumla, L, Sanmeema, N, Chaiwarith, R, Sirisanthana, T, Kotarathititum, W, Praparattanapan, J, Kantipong, P, Kambua, P, Ratanasuwan, W, Sriondee, R, Nguyen, K, Bui, H, Nguyen, D, Cuong, D, An, N, Luan, N, Sohn, A, Ross, J, Petersen, B, Cooper, D, Jiamsakul, A, Boettiger, D, Ellis, D, Bloch, M, Agrawal, S, Vincent, T, Allen, D, Smith, D, Rankin, A, Baker, D, Templeton, D, Jackson, E, Mccallum, K, Ryder, N, Sweeney, G, Carr, A, Macrae, K, Hesse, K, Finlayson, R, Gupta, S, Langton-Lockton, J, Shakeshaft, J, Brown, K, Idle, S, Arvela, N, Varma, R, Lu, H, Couldwell, D, Eswarappa, S, Furner, V, Cabrera, G, Fernando, S, Cogle, A, Lawrence, C, Mulhall, B, Boyd, M, Petoumenos, K, Puhr, R, Huang, R, Han, A, Gunathilake, M, Payne, R, O'Sullivan, M, Croydon, A, Russell, D, Cashman, C, Roberts, C, Sowden, D, Taing, K, Marshall, P, Orth, D, Youds, D, Rowling, D, Latch, N, Warzywoda, E, Dickson, B, Donohue, W, Edwards, S, Boyd, S, Roth, N, Lau, H, Read, T, Silvers, J, Zeng, W, Hoy, J, Watson, K, Bryant, M, Price, S, Woolley, I, Giles, M, Korman, T, Williams, J, Nolan, D, Allen, A, Guelfi, G, Mills, G, Wharry, C, Raymond, N, and Bargh, K

Subjects
Male, viruses, HIV Infections, Men who have sex with men, Cohort Studies, 0302 clinical medicine, Risk Factors, Antiretroviral therapy, Cohort study, HIV, Kaposi sarcoma, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, HIV-1, Humans, Middle Aged, Sarcoma, Kaposi, Viral Load, Young Adult, 030212 general & internal medicine, Articles and Commentaries, Incidence (epidemiology), Hazard ratio, virus diseases, Sarcoma, 3. Good health, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, Coinfection, Microbiology (medical), antiretroviral therapy, 610 Medicine & health, Kaposi, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 360 Social problems & social services, medicine, cohort study, business.industry, medicine.disease, Confidence interval, business, Demography
Abstract

Background We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. Methods We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). Results We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were

Published
2017
Full Text
View/download PDF

37. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Author

Castagna, Antonella, Maggiolo, Franco, Penco, Giovanni, Wright, David, Mills, Anthony, Grossberg, Robert, Molina, Jean-Michel, Chas, Julie, Durant, Jacques, Moreno, Santiago, Doroana, Manuela, Ait-Khaled, Mounir, Huang, Jenny, Min, Sherene, Song, Ivy, Vavro, Cindy, Nichols, Garrett, Yeo, Jane M., Aberg, J., Akil, B., Arribas, J. R., Baril, J.-G., Blanco Arévalo, J. L., Blanco Quintana, F., Blick, G., Boix Martínez, V., Bouchaud, O., Branco, T., Bredeek, U. F., Castro Iglesias, M., Clumeck, N., Conway, B., DeJesus, E., Delassus, J.-L., De Truchis, P., Di Perri, G., Di Pietro, M., Duggan, J., Duvivier, C., Elion, R., Eron, J., Fish, D., Gathe, J., Haubrich, R., Henderson, H., Hicks, C., Hocqueloux, L., Hodder, S., Hsiao, C.-B., Katlama, C., Kozal, M., Kumar, P., Lalla-Reddy, S., Lazzarin, A., Leoncini, F., Llibre, J. M., Mansinho, K., Morlat, P., Mounzer, K., Murphy, M., Newman, C., Nguyen, T., Nseir, B., Philibert, P., Pialoux, G., Poizot-Martin, I., Ramgopal, M., Richmond, G., Salmon Ceron, D., Sax, P., Scarsella, A., Sension, M., Shalit, P., Sighinolfi, L., Sloan, L., Small, C., Stein, D., Tashima, K., Tebas, P., Torti, C., Tribble, M., Troisvallets, D., Tsoukas, C., Viciana Fernández, P., Ward, D., Wheeler, D., Wilkin, T., Yeni, G.-P., Louise Martin-Carpenter, J., Uhlenbrauck, Gina, Castagna, Antonella, Maggiolo, Franco, Penco, Giovanni, Wright, David, Mills, Anthony, Grossberg, Robert, Molina Jean, Michel, Chas, Julie, Durant, Jacque, Moreno, Santiago, Doroana, Manuela, Ait Khaled, Mounir, Huang, Jenny, Min, Sherene, Song, Ivy, Vavro, Cindy, Nichols, Garrett, and Yeo Jane, M.

Subjects
Adult, Male, medicine.medical_specialty, Anti-HIV Agents, Pyridones, Population, Integrase inhibitor, HIV Infections, Pilot Projects, Quinolones, Pharmacology, Gastroenterology, Piperazines, Raltegravir Potassium, Major Articles and Brief Reports, chemistry.chemical_compound, Internal medicine, Drug Resistance, Viral, Oxazines, medicine, Humans, Immunology and Allergy, education, education.field_of_study, Bictegravir, elvitegravir resistance, Elvitegravir, business.industry, integrase inhibitor, DTG, Middle Aged, Viral Load, Raltegravir, Pyrrolidinones, dolutegravir, Infectious Diseases, chemistry, Dolutegravir, HIV-1, HIV/AIDS, raltegravir resistance, RNA, Viral, Female, business, Heterocyclic Compounds, 3-Ring, Viral load, medicine.drug
Abstract

Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INI-resistant virus received DTG 50 mg BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with ≥1 fully active drug and DTG continued. The primary efficacy endpoints were the mean change from baseline in plasma HIV-1 RNA at day 8 and the proportion of subjects with HIV-1 RNA

Published
2014
Full Text
View/download PDF

40. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Author

Orkin, Chloe, primary, Molina, Jean-Michel, additional, Negredo, Eugenia, additional, Arribas, José R, additional, Gathe, Joseph, additional, Eron, Joseph J, additional, Van Landuyt, Erika, additional, Lathouwers, Erkki, additional, Hufkens, Veerle, additional, Petrovic, Romana, additional, Vanveggel, Simon, additional, Opsomer, Magda, additional, Ajana, F, additional, Arribas, JR, additional, Bailey, J, additional, Benson, P, additional, Berenguer, J, additional, Bhatti, L, additional, Blaxhult, A, additional, Brar, I, additional, Bredeek, UF, additional, Brinson, C, additional, Brunetta, J, additional, Casado, J, additional, Clarke, A, additional, Conway, B, additional, Cotte, L, additional, Crofoot, G, additional, Cunningham, D, additional, de Vente, J, additional, De Wit, S, additional, DeJesus, E, additional, Dietz, C, additional, Dretler, R, additional, Eron, J, additional, Fehr, J, additional, Felizarta, F, additional, Fichtenbaum, C, additional, Flamholc, L, additional, Florence, E, additional, Galindo, MJ, additional, Gallant, J, additional, Gasiorowski, J, additional, Gatell, JM, additional, Gathe, J, additional, Gazzard, BG, additional, Girard, P-M, additional, Gisslèn, M, additional, Gutierrez, F, additional, Gutierrez, MDM, additional, Hagins, D, additional, Halota, W, additional, Henn, S, additional, Henry, WK, additional, Horban, A, additional, Huhn, G, additional, Iribarren, JA, additional, Jain, M, additional, Johnson, MA, additional, Katlama, C, additional, Klein, M, additional, Knobel, H, additional, Lucasti, C, additional, Martorell, C, additional, McDonald, C, additional, Mills, A, additional, Molina, J-M, additional, Morales-Ramirez, J, additional, Mounzer, K, additional, Moutschen, M, additional, Murphy, D, additional, Nahass, R, additional, Negredo, E, additional, Olivet, H, additional, Orkin, C, additional, Osiyemi, O, additional, Perez-Valero, I, additional, Piekarska, A, additional, Pineda, JA, additional, Podzamczer, D, additional, Poizot-Martin, I, additional, Portilla Sogorb, J, additional, Post, F, additional, Prelutsky, D, additional, Pulido, F, additional, Rachlis, A, additional, Raffi, F, additional, Ramgopal, M, additional, Rashbaum, B, additional, Rauch, A, additional, Rey, D, additional, Reynes, J, additional, Ricart, C, additional, Richmond, G, additional, Rivero, A, additional, Ruane, P, additional, Gil, I Santos, additional, Scarsella, A, additional, Scribner, A, additional, Shafran, S, additional, Shalit, P, additional, Shamblaw, D, additional, Slim, J, additional, Stoeckle, M, additional, Tashima, K, additional, Teicher, E, additional, Thalme, A, additional, Ustianowski, A, additional, Van Wijngaerden, E, additional, Vandekerckhove, L, additional, Vandercam, B, additional, Voskuhl, G, additional, Walmsley, S, additional, Ward, D, additional, Waters, L, additional, Wilkin, A, additional, Witor, A, additional, and Yazdanpanah, Y, additional

Published
2018
Full Text
View/download PDF

45. HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

Author

Eron, J. J., Bateson, R., Richman, D. D., Anderson, E. M., Margolis, D. M., Bosch, R. J., Kearney, M. F., Kuruc, J. D., Robertson, K. R., Coffin, J. M., Strain, M. C., Hazuda, D. J., Crooks, A. M., Tripathy, M. K., Kashuba, A. D., Archin, N. M., Dahl, N. P., and Yang, K.-H.

Subjects
genetic structures, sense organs
Abstract

Background. A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA expression within resting CD4+ T cells of treated, aviremic human immunodeficiency virus (HIV)–positive participants. The ability of multiple exposures to VOR to repeatedly disrupt latency has not been directly measured, to our knowledge.

Published
2014
Full Text
View/download PDF

48. Irish Neurological Association: Proceedings of the 17th Annual Meeting held on the 6th and 7th November, 1981, at the Regional Hospital, Wilton, Cork.

Author

Keohane, C., Phillips, J., Keane, T., Devlin, J., Gray, J., Johnston, R., Gordon, D., Feely, M. P., O’Laoire, S, A., Harrington, H., Eron, J., Shinnar, M., Hallett, M., Maguire, P., Headon, D., Mansfield, M., Martin, E. A., Hutchinson, M., Durward, W. F., Draper, Ronald, O’Hare, J., Callaghan, N., Murnaghan, D. J., Benan, Peter, Watts, Helen, Graham, David I., Kennedy, Peter G. E., Sandilands, Gavin, Feely, M., Calvert, R., Gibson, J., Coakley, D., O’Dwyer, J. A., Kaar, G. F., Fraher, J. P., Rossiter, J. P., Fraher, J. P., O’Sullivan, V. R., Johnston, R. A., Sklar, F. H., Sullivan, P., Callaghsn, N., O’Sullivan, D., Kantamaneni, B. D., Curzon, G., Martin, E. A., Phillips, J., O’Dwyer, J., Bone, Ian, Weir, Andrew, Kennedy, Dermot, Quigley, C., Feely, M., Galvin, R., O’Boyle, P., O’Keeffe, F., Murphy, J., Ward, M., Murphy, S. F., and Byrnes, Dermot P.

Published
1982
Full Text
View/download PDF

49. Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era

Author

Burkholder, G. A., Napravnik, S., Deeks, S. G., Patel, M. R., Gopal, S., Reid, E. G., Yanik, E. L., Rodriguez, B., Richards, K. L., Achenbach, C. J., Moore, R. D., Cole, S. R., Mayer, K. H., Eron, J. J., and Kitahata, M. M.

Subjects
hemic and lymphatic diseases
Abstract

Lymphoma is the leading cause of cancer-related death among HIV-infected patients in the antiretroviral therapy (ART) era.

Published
2013
Full Text
View/download PDF

50. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy

Author

Berzins, B. I., Rinaldo, C. R., Taiwo, B., Zheng, L., Kuritzkes, D. R., Eron, J. J., Kim, P. S., Matining, R. M., Lederman, M. M., Jennings, A., and Wilson, C. C.

Subjects
biochemical phenomena, metabolism, and nutrition
Abstract

One of the goals of antiretroviral therapy (ART) is to attenuate HIV-induced systemic immune activation and inflammation. We determined the dynamics of biomarkers of immune activation, microbial translocation and inflammation during initial ART with a nucleos(t)ide-sparing regimen of darunavir/ritonavir plus raltegravir. We also evaluated associations between these biomarkers and the virological response to the regimen.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results